In Brief: General Surgical Innovations
This article was originally published in The Gray Sheet
Executive Summary
General Surgical Innovations: Firm gains 510(k) clearance for combination balloon-dissector/tissue-expander instrument for use in plastic and reconstructive surgery procedures. The device combines the firm's proprietary balloon dissector technology with "a traditional tissue expander" to allow "faster and easier tissue expansion procedures," the firm claims. Separately, the Cupertino, California firm reports its Endosaph minimally invasive saphenous vein harvesting system for coronary bypass surgery was used successfully in its first commercial application at the Franciscan Medical Center in Dayton, Ohio. Endosaph was launched last month at the American College of Surgeons meeting in Chicago ("The Gray Sheet" Oct. 20, In Brief)...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.